Direct data includes those data assets typically provided to the manufacturer as a function of other agreements such as fee for service, rebates, coupon programs and chargebacks.
IntegriChain claimed that DNA provides 100% visibility to commercial demand in a low-latency business insight platform. The company said that its DNA platform has been built upon a SaaS architecture and scales to support dynamic analysis of a billion and transaction volumes with minimal latency. The architecture, data warehousing and analytic capabilities of DNA can be accessed via a zero-footprint web interface, further reducing the total cost of ownership for IntegriChain’s customers.
As part of the DNA: NextGen Analytics platform, IntegriChain is providing customers with a series of advanced analytical modules DNA: Channel, DNA: Chargeback Validation and DNA: Measurement of Retail Inventorya to maximize the value of Direct Data within multiple functions of the commercial pharmaceutical organisation, including Trade Operations, Finance, Managed Markets and Brand Marketing.
Kevin Leininger, CEO of IntegriChain, said: Poor data quality, high cost, high latency and the historical ad-hoc nature of projects in our industry have created pressure for pharmaceutical executives. Pre-existing solutions have simply been inadequate to allow manufacturers to build a sufficient value proposition around what should be a widely leveraged, shared data asset.
DNA is a low latency platform that uses a customer’s own data to quickly and inexpensively answer a whole host of questions critical to the new commercial model emerging in pharma. DNA solves manufacturers’ inherent data challenges.